These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21603651)

  • 41. Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.
    Munseri PJ; Kroidl A; Nilsson C; Joachim A; Geldmacher C; Mann P; Moshiro C; Aboud S; Lyamuya E; Maboko L; Missanga M; Kaluwa B; Mfinanga S; Podola L; Bauer A; Godoy-Ramirez K; Marovich M; Moss B; Hoelscher M; Gotch F; Stöhr W; Stout R; McCormack S; Wahren B; Mhalu F; Robb ML; Biberfeld G; Sandström E; Bakari M
    PLoS One; 2015; 10(4):e0119629. PubMed ID: 25875843
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.
    Launay O; Durier C; Desaint C; Silbermann B; Jackson A; Pialoux G; Bonnet B; Poizot-Martin I; Gonzalez-Canali G; Cuzin L; Figuereido S; Surenaud M; Ben Hamouda N; Gahery H; Choppin J; Salmon D; Guérin C; Bourgault Villada I; Guillet JG;
    PLoS One; 2007 Aug; 2(8):e725. PubMed ID: 17712402
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasmid DNA vaccination using skin electroporation promotes poly-functional CD4 T-cell responses.
    Bråve A; Nyström S; Roos AK; Applequist SE
    Immunol Cell Biol; 2011 Mar; 89(3):492-6. PubMed ID: 20838412
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.
    Eller MA; Slike BM; Cox JH; Lesho E; Wang Z; Currier JR; Darden JM; Polonis VR; Vahey MT; Peel S; Robb ML; Michael NL; Marovich MA
    PLoS One; 2011; 6(9):e24254. PubMed ID: 21949699
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
    Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL
    Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.
    Jin X; Morgan C; Yu X; DeRosa S; Tomaras GD; Montefiori DC; Kublin J; Corey L; Keefer MC;
    Vaccine; 2015 May; 33(20):2347-53. PubMed ID: 25820067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation.
    Otten GR; Schaefer M; Doe B; Liu H; Megede JZ; Donnelly J; Rabussay D; Barnett S; Ulmer JB
    Vaccine; 2006 May; 24(21):4503-9. PubMed ID: 16181711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial.
    Haidari G; Cope A; Miller A; Venables S; Yan C; Ridgers H; Reijonen K; Hannaman D; Spentzou A; Hayes P; Bouliotis G; Vogt A; Joseph S; Combadiere B; McCormack S; Shattock RJ
    Sci Rep; 2017 Oct; 7(1):13011. PubMed ID: 29026141
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
    Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
    PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.
    Catanzaro AT; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Gu L; Martin JE; Novik L; Chakrabarti BK; Butman BT; Gall JG; King CR; Andrews CA; Sheets R; Gomez PL; Mascola JR; Nabel GJ; Graham BS;
    J Infect Dis; 2006 Dec; 194(12):1638-49. PubMed ID: 17109335
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation.
    Cristillo AD; Weiss D; Hudacik L; Restrepo S; Galmin L; Suschak J; Draghia-Akli R; Markham P; Pal R
    Biochem Biophys Res Commun; 2008 Feb; 366(1):29-35. PubMed ID: 18036339
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
    Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
    J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
    Kibuuka H; Berkowitz NM; Millard M; Enama ME; Tindikahwa A; Sekiziyivu AB; Costner P; Sitar S; Glover D; Hu Z; Joshi G; Stanley D; Kunchai M; Eller LA; Bailer RT; Koup RA; Nabel GJ; Mascola JR; Sullivan NJ; Graham BS; Roederer M; Michael NL; Robb ML; Ledgerwood JE;
    Lancet; 2015 Apr; 385(9977):1545-54. PubMed ID: 25540891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo electroporation enhances vaccine-mediated therapeutic control of human papilloma virus-associated tumors by the activation of multifunctional and effector memory CD8
    Sales NS; Silva JR; Aps LRMM; Silva MO; Porchia BFMM; Ferreira LCS; Diniz MO
    Vaccine; 2017 Dec; 35(52):7240-7249. PubMed ID: 29174677
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16).
    Launay O; Surenaud M; Desaint C; Ben Hamouda N; Pialoux G; Bonnet B; Poizot-Martin I; Gonzales G; Cuzin L; Bourgault-Villada I; Lévy Y; Choppin J; Durier C
    Vaccine; 2013 Sep; 31(40):4406-15. PubMed ID: 23850610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.
    McElrath MJ; De Rosa SC; Moodie Z; Dubey S; Kierstead L; Janes H; Defawe OD; Carter DK; Hural J; Akondy R; Buchbinder SP; Robertson MN; Mehrotra DV; Self SG; Corey L; Shiver JW; Casimiro DR;
    Lancet; 2008 Nov; 372(9653):1894-1905. PubMed ID: 19012957
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses.
    Jiang J; Ramos SJ; Bangalore P; Fisher P; Germar K; Lee BK; Williamson D; Kemme A; Schade E; McCoy J; Muthumani K; Weiner DB; Humeau LM; Broderick KE
    Vaccine; 2019 Jun; 37(29):3832-3839. PubMed ID: 31174938
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle.
    Lin F; Shen X; McCoy JR; Mendoza JM; Yan J; Kemmerrer SV; Khan AS; Weiner DB; Broderick KE; Sardesai NY
    Vaccine; 2011 Sep; 29(39):6771-80. PubMed ID: 21199706
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses.
    Wang Q; Jiang W; Chen Y; Liu P; Sheng C; Chen S; Zhang H; Pan C; Gao S; Huang W
    J Virol; 2014 Feb; 88(4):1924-34. PubMed ID: 24284319
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy.
    Wilson CC; Newman MJ; Livingston BD; MaWhinney S; Forster JE; Scott J; Schooley RT; Benson CA
    Clin Vaccine Immunol; 2008 Jun; 15(6):986-94. PubMed ID: 18400976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.